Log In
BCIQ
Print this Print this
 

Apoxxim

  Manage Alerts
Collapse Summary General Information
Company Riboxx GmbH
DescriptionToll-like receptor 3 (TLR3) ligand
Molecular Target Toll-like receptor 3 (TLR3)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat TLR3-positive cancer
Regulatory Designation
PartnerTollys S.A.S.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/04/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today